J’Onco Mentor Version 9.09 — CNS PRIMARY

Desktop version. Mobile app coming.

WHAT IS J’ONCO MENTOR?LUNGBREASTHEAD & NECKPROSTATEENDOMETRIUMLIVERADRENAL GLANDKIDNEYTHYROIDBLADDERCOLON & RECTUMMELANOMA OF SKINPANCREASSTOMACHCNSHEMATOPOIETIC DISORDERSTOP CANCER SITESSTORE MANUALRADIATION GUIDESTATE REPORTABILITYICD-10-CM / SECONDARY DXODS RESOURCES

DIAGNOSIS YEAR

Select the diagnosis year first. J’Onco Mentor uses it to establish the standards cycle and to drive year-sensitive routing in this module.

SEER manual—
NAACCR cycle—
Staging context—
Standards statusSelect year
No diagnosis year selected. Year-dependent schema, staging, SSDI, grade, surgery, and manual guidance should not be assumed.

INTERACTIVE CNS PRIMARY-SITE SELECTOR

Realistic sagittal CNS anatomy atlas with labeled brain lobes, meninges, cranial nerves, pituitary, pineal gland, brain stem and spinal cord

Select a cyan marker on the realistic CNS atlas to drive the primary-site code and laterality logic. Click the active marker again to deselect it.

Type a code or name, or use the dropdown below. Both controls stay synchronized.

Expanded CNS histology selector in the Primary Site box. It includes malignant and non-malignant CNS choices used in current SEER/ICD-O-oriented workflows and stays synchronized with the Histology section. Rare terms not listed should still be verified in current ICD-O-3.2 / Solid Tumor Rules.

Selecting an additional site immediately adds it to the anatomy selection and recalculates the primary-site result.

CALCULATED PRIMARY SITE
—
No CNS site selected.
SELECTED CNS REGIONS
  • No regions selected.

REPORTABILITY & BEHAVIOR

Malignant CNS

Use the current Malignant CNS and Peripheral Nerves Solid Tumor Rules for applicable reportable sites/histologies.

Benign / Borderline CNS

Intracranial and intraspinal benign/borderline tumors can be reportable. For spinal tumors, intradural location is important; extracranial/extradural nerve tumors may not meet CNS reportability rules.

Intracranial glands

Pituitary, craniopharyngeal duct, and pineal gland are included in the CNS Solid Tumor Rules site groups when applicable.

Do not infer reportability from tumor name alone. Confirm site, behavior, diagnosis year, and the current Solid Tumor Rules / SEER coding guidelines.

CNS HISTOLOGY / TUMOR FAMILY

Type a code or name, or use the dropdown below. Both controls stay synchronized.
SELECTED HISTOLOGY
—
No histology selected.

Integrated CNS diagnosis

Modern CNS diagnoses may combine morphology with molecular findings. Use the final documented integrated diagnosis and the current ICD-O-3.2 / SEER Solid Tumor Rules when assigning the definitive histology and behavior.

The same expanded histology menu is available in the Primary Site selector above. Rare or newly introduced terms should be verified in current ICD-O-3.2 / Solid Tumor Rules.

Diffuse astrocytic tumors

Includes astrocytoma and glioblastoma families. Molecular status can be integral to the final WHO diagnosis.

Oligodendroglial tumors

Oligodendroglioma diagnosis incorporates IDH mutation and 1p/19q co-deletion status.

Ependymal / embryonal

Includes ependymal tumors, medulloblastoma, and other embryonal families.

MULTIPLE PRIMARY RULES — CNS

Use the correct CNS rule set

Malignant CNS and Non-Malignant CNS have distinct site-group instructions and tables. Do not apply the Other Sites rules to CNS tumors.

Site + histology relationships matter

CNS multiple-primary decisions can depend on whether tumors are on the same or different rows of the current Solid Tumor Rules tables, as well as timing and transformation/progression rules.

J'Onco Mentor should support review of the rule logic, but the current SEER Solid Tumor Rules remain the controlling source for final multiple-primary and histology coding.

MOLECULAR MARKERS / SSDI

NAACCR #3816

Brain Molecular Markers

Captures clinically important molecularly defined brain tumor subtypes that may not be distinguishable by the base ICD-O-3 code alone.

IDH
1p/19q
NAACCR #3889

MGMT methylation

Used for applicable brain histologies. Record the documented methylation result according to the current schema.

Integrated diagnosis

WHO CNS diagnoses increasingly combine histology with molecular findings. Do not substitute a molecular marker result for the documented final integrated diagnosis.

WHO CNS GRADE

Use the documented grade and current Grade Manual rules. Numeric WHO grades take priority when available.

Grade data items

Grade may be collected as Clinical, Pathological, Post-Therapy Clinical, or Post-Therapy Pathological depending on the case and treatment sequence.

AJCC STAGING SCHEMA / TNM ENTRY

PATHOLOGIC STAGING CRITERIA — CNS / BRAIN

Qualifying evidence: Most primary CNS tumors do not use conventional AJCC pTNM. Use the applicable WHO CNS tumor classification, histology, molecular findings and grade. Do not generate pT or pN categories where no AJCC TNM schema applies.

pT / pN: Assign only categories supported by the actual pathological evidence and the site-specific AJCC rules. A diagnosis-confirming biopsy does not automatically establish a pathological primary tumor category.

pM: Pathologically proven distant metastasis may support pM1 where the chapter permits; AJCC does not use pM0.

Treatment sequence: Distinguish initial pathological classification (pTNM) from post-neoadjuvant classification (ypTNM). Confirm eligibility, histology, staging chapter and diagnosis-year edition before finalizing.

Source / verification: AJCC · SEER tools and manuals. Educational overview only; verify exact chapter-specific criteria in the licensed AJCC manual.

Reference traceabilitySEER*RSA CNS schemas ↗
Important: Conventional AJCC TNM stage grouping is not the native staging system for the Brain, CNS Other, or Intracranial Gland pathways. The fields below are provided so an ODS can capture TNM-style values required by a local system without implying an AJCC stage group.


TNM CAPTURE

T—
N—
M—

—

Use the CNS STAGING section for the actual SEER schema and Summary Stage workflow.

CNS STAGING

SCHEMA IDENTIFICATION

Select site + histology
Schema will calculate from site, histology, behavior, and diagnosis year.
Choose a primary site and histology to identify the applicable SEER*RSA schema.

STAGING METHOD

—

The applicable staging method will appear after schema identification.

AJCC status pending
BRAINC70.0 and C71.0–C71.9 when the selected histology remains in the Brain schema.
CNS OTHERSpinal meninges, spinal cord, cauda equina, cranial nerves, overlapping CNS, and nervous system NOS when schema-eligible.
INTRACRANIAL GLANDPituitary, craniopharyngeal duct, and pineal gland when the histology remains in the intracranial-gland schema.
MEDULLOBLASTOMASeparate SEER schema for specified embryonal/medulloblastoma histologies diagnosed 2023+.
Brain vs CNS staging: J’Onco Mentor now routes the case to the applicable Brain, CNS Other, Intracranial Gland, or Medulloblastoma SEER schema from the selected primary site, histology, behavior, and diagnosis year. For the core CNS schemas, SEER*RSA identifies Summary Stage as the applicable staging system; the AJCC Brain and Spinal Cord framework does not produce a conventional TNM stage group here.

EOD Primary Tumor

Use the selected schema to code confinement, extension within the CNS, crossing the midline when specifically documented, and extension to adjacent structures.

EOD Regional Nodes

Regional lymph-node staging is generally not applicable to primary CNS-schema tumors. Follow the schema-specific instructions.

EOD Mets / Dissemination

Captures qualifying discontinuous spread, including CNS/CSF dissemination such as leptomeningeal or drop metastases and extra-neural distant disease when defined by the schema.

ODS reminder: Schema selection is driven by site, histology, behavior, and diagnosis year. Some histologies arising in CNS-area sites route to another SEER schema (for example, Medulloblastoma or Soft Tissue Head and Neck). Do not infer AJCC eligibility from anatomy alone.

TREATMENT / SURGERY REFERENCE

Resection

Document extent of surgery from operative and pathology reports. Gross total, subtotal, and biopsy-only procedures should not be inferred from imaging language alone.

Radiation

Capture modality, target, and course according to STORE/NAACCR rules; CNS treatment may include focal radiation, stereotactic techniques, or craniospinal fields depending on disease.

Systemic therapy

Therapy varies substantially by histology and molecular profile. This section is educational and should not be used as a treatment recommendation engine.

COMMON SPREAD / DISSEMINATION — PRIMARY CNS

Primary CNS tumors more commonly disseminate within the CNS/CSF pathways than to extracranial organs. Patterns are highly histology-dependent.

Leptomeninges / CSF

Leptomeningeal dissemination and positive CSF can represent distant CNS spread depending on the schema context.

Spinal canal / “drop” metastases

Seen with selected CNS histologies and captured in EOD Mets when discontinuous spread is documented.

Other CNS sites

Discontiguous intracranial or intraspinal spread may occur depending on histology.

Extra-neural metastasis

Possible but uncommon for primary CNS tumors; code only when documented.

SOURCES

2027 standards cycle: Use the 2027 SEER Program Coding and Staging Manual, Solid Tumor Rules 2027, STORE 2027, NAACCR v27 resources, Summary Stage v3.4, and the current diagnosis-year SEER*RSA/EOD schema as applicable. Historical cases may require prior-year instructions.